Assignee
AGENUS INC
US49 patents
Top patents by PatentIndex Score
US10280226B2May 7, 2019
Anti-GITR antibodies and methods of use thereof
AGENUS INC17 citations93
US10259882B2Apr 16, 2019
Anti-OX40 antibodies
AGENUS INC16 citations93
US10155818B2Dec 18, 2018
Anti-GITR antibodies and methods of use thereof
AGENUS INC17 citations93
US10639368B2May 5, 2020
Anti-TIM-3 antibodies and methods of use thereof
AGENUS INC15 citations92
US10144779B2Dec 4, 2018
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC12 citations92
US11638755B2May 2, 2023
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC4 citations84
US11242385B2Feb 8, 2022
Anti-CD137 antibodies and methods of use thereof
AGENUS INC8 citations84
US10836830B2Nov 17, 2020
Antibodies and methods of use thereof
AGENUS INC12 citations84
US10479833B2Nov 19, 2019
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC8 citations84
US10323091B2Jun 18, 2019
Anti-PD-1 antibodies and methods of use thereof
AGENUS INC5 citations83
US11013802B2May 25, 2021
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC5 citations82
US10912831B1Feb 9, 2021
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC6 citations82
US10912828B2Feb 9, 2021
Anti-TIM-3 antibodies and methods of use thereof
AGENUS INC4 citations82
US10626181B2Apr 21, 2020
Nucleic acids encoding anti-OX40 antibodies
AGENUS INC7 citations82
US10577426B2Mar 3, 2020
Anti-GITR antibodies and methods of use thereof
AGENUS INC3 citations82
US11267889B2Mar 8, 2022
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC2 citations73
US11345755B2May 31, 2022
Anti-PD-1 antibodies and methods of use thereof
AGENUS INC2 citations72
US11332536B2May 17, 2022
Vectors comprising nucleic acids encoding anti-OX40 antibodies
AGENUS INC1 citations72
US10829559B2Nov 10, 2020
Anti-GITR antibodies and methods of use thereof
AGENUS INC1 citations72
US11993653B2May 28, 2024
Antibodies and methods of use thereof
AGENUS INC2 citations71
US11472883B2Oct 18, 2022
Methods of administering anti-OX40 antibodies
AGENUS INC1 citations71
US11447557B2Sep 20, 2022
Antibodies and methods of use thereof
AGENUS INC3 citations71
US11136404B2Oct 5, 2021
Anti-OX40 antibodies
AGENUS INC1 citations71
US11021537B2Jun 1, 2021
Anti-TIGIT antibodies and methods of use thereof
AGENUS INC2 citations71
US10882908B2Jan 5, 2021
Anti-LAG-3 antibodies and methods of use thereof
AGENUS INC2 citations71
US10844119B2Nov 24, 2020
Anti-LAG-3 antibodies and methods of use thereof
AGENUS INC3 citations71
US10800849B2Oct 13, 2020
Anti-GITR antibodies and methods of use thereof
AGENUS INC2 citations71
US11692042B2Jul 4, 2023
Anti-CD73 antibodies and methods of use thereof
AGENUS INC3 citations69
US10640535B2May 5, 2020
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
AGENUS INC2 citations67
US12492257B2Dec 9, 2025
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC0 citations62
US11897962B2Feb 13, 2024
Anti-GITR antibodies and methods of use thereof
AGENUS INC0 citations62
US12492393B2Dec 9, 2025
Anti-CD137 antibodies and methods of use thereof
AGENUS INC0 citations61
US12246066B2Mar 11, 2025
Anti-CTLA-4 antibodies and methods of use thereof
AGENUS INC0 citations61
US12187795B2Jan 7, 2025
Anti-LAG-3 antibodies and methods of use thereof
AGENUS INC0 citations61
US11993651B2May 28, 2024
Anti-lag-3 antibodies and methods of use thereof
AGENUS INC0 citations61
US11401335B2Aug 2, 2022
Anti-GITR antibodies and methods of use thereof
AGENUS INC0 citations61
US11359028B2Jun 14, 2022
Anti-OX40 antibodies and anti-GITR antibodies
AGENUS INC1 citations61
US11098117B2Aug 24, 2021
Anti-CD137 antibodies and methods of use thereof
AGENUS INC0 citations61
US12011481B2Jun 18, 2024
Anti-TIM-3 antibodies and methods of use thereof
AGENUS INC0 citations60
US11839653B2Dec 12, 2023
Anti-TIM-3 antibodies and methods of use thereof
AGENUS INC0 citations60
US11065317B2Jul 20, 2021
Heat shock protein-binding peptide compositions and methods of use thereof
AGENUS INC1 citations57
US11414458B2Aug 16, 2022
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
AGENUS INC0 citations56
US11680098B2Jun 20, 2023
Antibodies that specifically bind human CD96
AGENUS INC1 citations54
US12479913B2Nov 25, 2025
Polynucleotide encoding anti-TIGIT and anti-CD96 antibodies
AGENUS INC0 citations53
US11718669B2Aug 8, 2023
Anti-TIGIT and anti-CD96 antibodies
AGENUS INC0 citations53
US10450373B2Oct 22, 2019
Anti-PD-1 antibodies and methods of use thereof
AGENUS INC0 citations51
US10502745B2Dec 10, 2019
Identification of antigen- or ligand-specific binding proteins
AGENUS INC0 citations49
US9645146B2May 9, 2017
Cell surface display, screening and production of proteins of interest
AGENUS INC0 citations45
US10568948B2Feb 25, 2020
Vaccines for treatment and prevention of cancer
AGENUS INC0 citations39